Insight Molecular Diagnostics (IMDX) Cash & Current Investments (2020 - 2025)
Historic Cash & Current Investments for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $19.4 million.
- Insight Molecular Diagnostics' Cash & Current Investments rose 47144.12% to $19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.4 million, marking a year-over-year increase of 47144.12%. This contributed to the annual value of $8.6 million for FY2024, which is 843.94% down from last year.
- Per Insight Molecular Diagnostics' latest filing, its Cash & Current Investments stood at $19.4 million for Q3 2025, which was up 47144.12% from $24.3 million recorded in Q2 2025.
- Over the past 5 years, Insight Molecular Diagnostics' Cash & Current Investments peaked at $59.8 million during Q1 2021, and registered a low of $3.4 million during Q3 2024.
- In the last 5 years, Insight Molecular Diagnostics' Cash & Current Investments had a median value of $20.4 million in 2022 and averaged $23.7 million.
- Its Cash & Current Investments has fluctuated over the past 5 years, first tumbled by 7612.53% in 2024, then surged by 47144.12% in 2025.
- Quarter analysis of 5 years shows Insight Molecular Diagnostics' Cash & Current Investments stood at $33.9 million in 2021, then plummeted by 39.66% to $20.4 million in 2022, then plummeted by 53.82% to $9.4 million in 2023, then decreased by 8.44% to $8.6 million in 2024, then surged by 124.98% to $19.4 million in 2025.
- Its Cash & Current Investments stands at $19.4 million for Q3 2025, versus $24.3 million for Q2 2025 and $31.0 million for Q1 2025.